Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004452 | 0.74 | HAVCR2 (0.39) | PDE10ASPRHTR2CHTR2B | |
| SCHEMBL15739828 | 0.74 | PDE10A (0.38) | PDE10ASPRHTR2AHTR2CHTR2B | |
| SCHEMBL13890356 | 0.71 | PDE10A (0.36) | PDE10ASPRHTR2AHTR2CHTR2B | |
| SCHEMBL18701564 | 0.70 | USP2 (0.41) | PDE10ASPRHTR2AHTR2CHTR2B | |
| SCHEMBL18711468 | 0.70 | L3MBTL1 (0.38) | PDE10ASPRHTR2AHTR2CHTR2B | |
| SCHEMBL1487918 | 0.70 | KMT2A (0.36) | PDE10ASPR | |
| SCHEMBL4003319 | 0.68 | KDM4C (0.41) | PDE10ASPRHTR2AHTR2CHTR2B | |
| SCHEMBL3999675 | 0.67 | GSK3B (0.43) | PDE10ASPR | |
| SCHEMBL6517226 | 0.67 | SPR (0.38) | PDE10ASPR | |
| SCHEMBL867071 | 0.62 | KDR (0.35) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | BDNF, NTRK2, NGF | PDE10A 234/4885SPR 2959/4885HTR2A 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.